LY2784544 – 10 mg

Brand:
Cayman
CAS:
1229236-86-5
Storage:
-20
UN-No:
Non-Hazardous - /

LY2784544 is a potent, ATP-competitive inhibitor of janus kinase 2 (JAK2) that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively).{27398} It also inhibits JAK2 containing the V617F mutation (IC50 = 20 nM), blocking STAT5 phosphorylation and proliferation of Ba/F3 pro-B-cells expressing this constitutively active JAK2 mutant form.{27398} When given by oral gavage, LY2784544 significantly reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets.{27398} JAK inhibitors, including LY2784544, may be useful in hematological malignancies.{27397}  

 

Out of stock

SKU: - Category:

Description

A potent, ATP-competitive inhibitor of JAK2 that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively); inhibits JAK2 containing the V617F mutation (IC50 = 20 nM); reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets


Formal name: 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)-imidazo[1,2-b]pyridazin-6-amine

Synonyms: 

Molecular weight: 470

CAS: 1229236-86-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|JAK Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|JAK/STAT Signaling||Research Area|Cell Biology|Cell Signaling|JAK Signaling